Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
Public ClinicalTrials.gov record NCT01873248. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Somatostatin receptor imaging with 68Ga-DOTATATE PET/CT (DOTATATE) is increasingly used for managing patients with neuroendocrine tumors. The objective of this study was to determine referring physicians' perspectives on the impact of DOTATATE on the management of neuroendocrine tumors.
Study identification
- NCT ID
- NCT01873248
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Early Phase 1
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 25, 2013
- Primary completion
- Jun 15, 2017
- Completion
- Jun 15, 2017
- Last update posted
- Jul 18, 2024
2013 – 2017
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Los Angeles, Nuclear Medicine Clinic of the Department of Molecular and Medical Pharmacology | Los Angeles | California | 90095 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Neuroendocrine Tumors trials
Other public records listing Neuroendocrine Tumors. Sorted by last update posted; newest first. Not a recommendation.
- NCT06448208: Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors Active, not recruiting
- NCT05000294: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Recruiting
- NCT02012699: Integrated Cancer Repository for Cancer Research Recruiting
- NCT07661420: 211At-MABG in Adults With Advanced Neuroendocrine Cancers Not yet recruiting
- NCT03935893: Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers Active, not recruiting
- NCT06122610: Using Novel Imaging to More Safely Treat Neuroendocrine Tumors Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01873248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 18, 2024 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01873248 live on ClinicalTrials.gov.